|Bid||39.00 x 4000|
|Ask||39.38 x 2200|
|Day's Range||38.85 - 39.35|
|52 Week Range||33.26 - 42.68|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||13.47|
|Forward Dividend & Yield||2.17 (5.41%)|
|Ex-Dividend Date||May 20, 2021|
|1y Target Est||N/A|
While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.
To expedite the search and process, the pharmaceutical company isn't the entity who signed the lease with Brandywine Realty Trust.
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks initially suffered […]